Literature DB >> 25766403

The role of C/EBP-β LIP in multidrug resistance.

Chiara Riganti1, Joanna Kopecka1, Elisa Panada1, Sara Barak1, Menachem Rubinstein2.   

Abstract

BACKGROUND: Chemotherapy triggers endoplasmic reticulum (ER) stress, which in turn regulates levels of the active (LAP) and the natural dominant-negative (LIP) forms of the transcription factor C/EBP-β. LAP upregulates and LIP downregulates the multidrug resistance (MDR) protein P-glycoprotein (Pgp), but it is not known how critical is their role in establishing MDR.
METHODS: Cell viability was quantitated by crystal violet staining and measuring absorbance at 540nm. Expression of various proteins was determined by immunoblotting. mRNA levels were determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). LIP and LAP were overexpressed using expression plasmids followed by selection with blasticidin. Tumor cells expressing doxycycline-inducible LIP were orthotopically implanted in mice (n = 15 mice per group), and tumor size was measured daily by caliper. Tumor sections were stained with hematoxylin and eosin and immunostained for Pgp, proliferation, and ER stress markers.
RESULTS: MDR cells do not express basal, chemotherapy-triggered, or ER stress-triggered LIP and fail to activate the CHOP-caspase-3 death-triggering axis upon ER stress or chemotherapy challenge. Overexpression of LIP reversed the MDR phenotype in vitro and in tumors implanted in mice. LIP was undetectable in MDR cells, probably due to its ubiquitination, which was 3.56-fold higher, resulting in lysosomal and proteasomal degradation of LIP.
CONCLUSIONS: Spontaneous and drug-selected MDR cells lack LIP, which is eliminated by ubiquitin-mediated degradation. Loss of LIP drives MDR not only by increasing Pgp expression but also by a two-fold attenuation of ER stress-triggered cell death.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25766403     DOI: 10.1093/jnci/djv046

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  18 in total

1.  PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy.

Authors:  Iris C Salaroglio; Elisa Panada; Enrico Moiso; Ilaria Buondonno; Paolo Provero; Menachem Rubinstein; Joanna Kopecka; Chiara Riganti
Journal:  Mol Cancer       Date:  2017-05-12       Impact factor: 27.401

2.  P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.

Authors:  Joanna Kopecka; Gregory M Rankin; Iris C Salaroglio; Sally-Ann Poulsen; Chiara Riganti
Journal:  Oncotarget       Date:  2016-12-27

3.  Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells.

Authors:  Elena Gazzano; Loretta Lazzarato; Barbara Rolando; Joanna Kopecka; Stefano Guglielmo; Costanzo Costamagna; Konstantin Chegaev; Chiara Riganti
Journal:  Front Pharmacol       Date:  2018-06-04       Impact factor: 5.810

Review 4.  Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer.

Authors:  Deep Pokharel; Ariane Roseblade; Vici Oenarto; Jamie F Lu; Mary Bebawy
Journal:  Ecancermedicalscience       Date:  2017-09-18

5.  C/EBPβ LIP augments cell death by inducing osteoglycin.

Authors:  Rina Wassermann-Dozorets; Menachem Rubinstein
Journal:  Cell Death Dis       Date:  2017-04-06       Impact factor: 8.469

6.  Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.

Authors:  Iris C Salaroglio; Elena Gazzano; Ahmad Abdullrahman; Eleonora Mungo; Barbara Castella; Gamal Eldein Fathy Abd-Ellatef Abd-Elrahman; Massimo Massaia; Massimo Donadelli; Menachem Rubinstein; Chiara Riganti; Joanna Kopecka
Journal:  J Exp Clin Cancer Res       Date:  2018-11-27

7.  Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2.

Authors:  Yuan Rong; Chun-Hui Yuan; Zhen Qu; Hu Zhou; Qing Guan; Na Yang; Xiao-Hua Leng; Lang Bu; Ke Wu; Fu-Bing Wang
Journal:  Sci Rep       Date:  2016-04-01       Impact factor: 4.379

8.  Integrating Enzymatic Self-Assembly and Mitochondria Targeting for Selectively Killing Cancer Cells without Acquired Drug Resistance.

Authors:  Huaimin Wang; Zhaoqianqi Feng; Youzhi Wang; Rong Zhou; Zhimou Yang; Bing Xu
Journal:  J Am Chem Soc       Date:  2016-12-01       Impact factor: 15.419

Review 9.  Interplay between P-Glycoprotein Expression and Resistance to Endoplasmic Reticulum Stressors.

Authors:  Milan Hano; Lenka Tomášová; Mário Šereš; Lucia Pavlíková; Albert Breier; Zdena Sulová
Journal:  Molecules       Date:  2018-02-06       Impact factor: 4.411

10.  Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.

Authors:  Linda Vidarsdottir; Rita Valador Fernandes; Vasilios Zachariadis; Ishani Das; Elin Edsbäcker; Ingibjorg Sigvaldadottir; Alireza Azimi; Veronica Höiom; Johan Hansson; Dan Grandér; Suzanne Egyházi Brage; Katja Pokrovskaja Tamm
Journal:  Melanoma Res       Date:  2020-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.